Lemaître V, O'Byrne T K, Borczuk A C, Okada Y, Tall A R, D'Armiento J
Division of Molecular Medicine, Department of Medicine, and. Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
J Clin Invest. 2001 May;107(10):1227-34. doi: 10.1172/JCI9626.
Matrix metalloproteinase-1 (MMP-1), or interstitial collagenase, has been hypothesized to contribute to the progression of the human atherosclerotic lesions by digesting the fibrillar collagens of the neointimal ECM. The apolipoprotein E knockout (apoE0) mouse model develops complex atherosclerotic lesions, but mice do not possess a homologue for MMP-1. To provide an in vivo evaluation of the role of MMP-1 in atherogenesis, we created a transgenic mouse model that expresses this enzyme specifically in the macrophage, under the control of the scavenger receptor A (SCAV) enhancer/promoter. The MMP-1 transgenic mice were crossed into the apoE0 background and fed an atherogenic diet for 16-25 weeks. Surprisingly, the transgenic mice demonstrated decreased lesion size compared with control littermates. The lesions of the transgenic animals were less extensive and immature, with fewer cellular layers and a diminished content of fibrillar collagen. There was no evidence of plaque rupture. Our data suggest that remodeling of the neointimal extracellular matrix by MMP-1 is beneficial in the progression of lesions.
基质金属蛋白酶-1(MMP-1),即间质胶原酶,据推测可通过消化新生内膜细胞外基质(ECM)的纤维状胶原,促进人类动脉粥样硬化病变的发展。载脂蛋白E基因敲除(apoE0)小鼠模型会形成复杂的动脉粥样硬化病变,但小鼠没有MMP-1的同源物。为了在体内评估MMP-1在动脉粥样硬化发生中的作用,我们创建了一种转基因小鼠模型,该模型在清道夫受体A(SCAV)增强子/启动子的控制下,在巨噬细胞中特异性表达这种酶。将MMP-1转基因小鼠与apoE0背景小鼠杂交,并给予致动脉粥样化饮食16至25周。令人惊讶的是,与对照同窝小鼠相比,转基因小鼠的病变大小减小。转基因动物的病变范围更小且不成熟,细胞层数更少,纤维状胶原含量减少。没有斑块破裂的迹象。我们的数据表明,MMP-1对新生内膜细胞外基质的重塑有利于病变的发展。